Patent ID: 9445990
Filing Date: 2016-09-20
CPC Classification: A61K,A61P

Claim Text:
1. An injectable formulation, comprising: between 5 mg/ml and 500 mg/ml of a tumor necrosis factor (TNF) inhibitor polypeptide having one or more of the following amino acid substitutions VIM; R31C; C69V; Y87H; C101A; and A145R, relative to a 157 amino acid long N-terminal portion of the amino acid sequence of SEQ ID NO:1; between 10 mM and 25 mM of a phosphate or citrate buffer; between 5% and 10% of a carbohydrate; and optionally NaCl, wherein the combined ionic strength of the buffer and the optional salt is an equivalent ionic strength of between 0.1M and 0.2M NaCl, wherein the formulation has a pH of between 6 and 7, is fluid at room temperature and at 37° C., and has a viscosity of 10 centipoise or less at room temperature, and wherein the formulation is configured to be delivered via an implantable infusion device.